{"groups":[{"description":"Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.","id":"FG000","title":"Tivantinib (Monotherapy or Combination)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"32"}],"type":"Progressive disease per RECIST"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Progressive disease per clinician"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"No reason provided"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Drug manufacturing ended"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"60"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"60"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Adult male and female participants previously enrolled in phase 1 or phase 2 studies of tivantinib (ARQ 197) were eligible for enrollment."}